Literature DB >> 12228912

Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.

Marie Annick Buendia1.   

Abstract

Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are two different subtypes of primary tumors arising from liver parenchymal cells. These tumors differ by many histoclinical characteristics, and comparative analysis of genetic alterations in HB and HCC might provide some clues on the molecular oncogenic pathways leading to hepatocyte transformation. Recent outcomes have been provided by the assessment of global genetic changes in tumor cells, using conventional cytogenetic approaches, PCR-based microsatellite analysis and Comparative genomic Hybridization (CGH). Cytogenetic studies of HB, microsatellite analysis of HCC and recent CHG data have outlined common and distinctive characters between the two tumor types. HBs are characterized by a low number of chromosomal changes, consisting mainly of gains at chromosomes 1q, 2, 8q, 17q, and 20. By contrast, HCCs harbor multiple chromosomal abnormalities, predominantly losses, with increased chromosomal instability in tumors associated with hepatitis B virus infection. Common alterations in HB and HCC include gain of chromosomes 1q, 8q, and 17q, and loss of 4q. Another important common feature shared by the two tumor types is the frequent activation of Wnt/beta-catenin signaling by stabilizing mutations of beta-catenin. Immunohistochemical analysis of beta-catenin has demonstrated nuclear/cytoplasmic accumulation of the protein in most HBs and in more than one third of HCCs. Strikingly, beta-catenin mutations are associated with chromosomal stability in both tumor types. Together, these studies define different pathways in liver cell transformation, reflecting various developmental stages and multiple risk factors. A detailed understanding of the molecular hits underlying liver tumorigenesis, combined with clinicopathological parameters, will permit an accurate evaluation of major targets for prognostic and therapeutic intervention. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228912     DOI: 10.1002/mpo.10180

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  17 in total

Review 1.  [Current status of diagnosis and treatment of hepatoblastoma].

Authors:  Purificación García-Miguel; Manuel López Santamaría
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

2.  Utilizing ethacrynic acid and ciclopirox olamine in liver cancer.

Authors:  Ahmad M Al-Dali; Hans Weiher; Ingo G H Schmidt-Wolf
Journal:  Oncol Lett       Date:  2018-09-20       Impact factor: 2.967

Review 3.  Molecular Pathogenesis of Liver Cancer.

Authors:  Mehmet Ozturk; Tugce Batur; Umut Ekin; Aybike Erdogan; Evin İscan; Umur Keles; Ozden Oz; Cigdem Ozen
Journal:  J Gastrointest Cancer       Date:  2017-09

4.  Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

Authors:  Sigal Kremer-Tal; Goutham Narla; Yingbei Chen; Eldad Hod; Analisa DiFeo; Steven Yea; Ju-Seog Lee; Myron Schwartz; Swan N Thung; Isabel M Fiel; Michaela Banck; Eran Zimran; Snorri S Thorgeirsson; Vincenzo Mazzaferro; Jordi Bruix; John A Martignetti; Josep M Llovet; Scott L Friedman
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

5.  Deregulation of Hippo kinase signalling in human hepatic malignancies.

Authors:  Hua Li; Andy Wolfe; Seth Septer; Genea Edwards; Xiaobo Zhong; Ahmad Bashar Abdulkarim; Sarangarajan Ranganathan; Udayan Apte
Journal:  Liver Int       Date:  2011-10-20       Impact factor: 5.828

6.  Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma.

Authors:  Valeria R Mas; Daniel G Maluf; Kellie J Archer; Kenneth Yanek; Xiangrong Kong; Laura Kulik; Chris E Freise; Kim M Olthoff; Rafik M Ghobrial; Paula McIver; Robert Fisher
Journal:  Mol Med       Date:  2008-12-15       Impact factor: 6.354

Review 7.  Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers.

Authors:  Masahiro Fujimuro; S Diane Hayward
Journal:  J Mol Med (Berl)       Date:  2004-01-09       Impact factor: 4.599

8.  p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein.

Authors:  Ya-Wen Chen; Seema Paliwal; Kyle Draheim; Steven R Grossman; Brian C Lewis
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

9.  Pharmacological inhibition of beta-catenin in hepatoblastoma cells.

Authors:  V Ellerkamp; J Lieber; C Nagel; J Wenz; S W Warmann; J Fuchs; S Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-12-25       Impact factor: 1.827

10.  Evaluating the effect of high-intensity focused ultrasound therapy on liver tumors using multislice CT perfusion.

Authors:  Xinshan Cao; Xingyue Jiang
Journal:  Oncol Lett       Date:  2012-12-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.